High-dose dexamethasone shifts the balance of stimulatory and inhibitory Fcγ receptors on monocytes in patients with primary immune thrombocytopenia

Blood

Volumn 117, Issue 6, 2011, Pages 2061-2069

  Liu, Xin Guang ^a   Ma, Shi Hi ^a,b   Sun, Jian Zhi ^a   Ren, Juan ^a   Shi, Yan ^a   Sun, Lin ^a   Dong, Xiao Yuan ^a   Qin, Ping ^a   Guo, Cheng Shan ^c   Hou, Ming ^a,d   Peng, Jun ^a,d  

^a SHANDONG UNIVERSITY   (China)

^b INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^c SHANDONG UNIVERSITY   (China)

^d BEIJING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR IIB; MESSENGER RNA;

ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MONOCYTE; PATHOGENESIS; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTOPENIA;

EID: 79951481124     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-295477     Document Type: Article

References (42)

1. Sohn HW, Pierce SK, Tzeng SJ. Live cell imaging reveals that the inhibitory FcgammaRIIB destabilizes B cell receptor membrane-lipid interactions and blocks immune synapse formation. J Immunol. 2008;180(2):793-799.
2. Liu W, Won Sohn H, Tolar P, Meckel T, Pierce SK. Antigen-induced oligomerization of the B cell receptor is an early target of FcgammaRIIB inhibition. J Immunol. 2010;184(4):1977-1989.
3. Su K, Yang H, Li X, et al. Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. J Immunol. 2007;178(5):3272-3280. (Pubitemid 46333211)
4. Carreño LJ, Pacheco R, Gutierrez MA, Jacobelli S, Kalergis AM. Disease activity in systemic lupus erythematosus is associated with an altered expression of low-affinity Fc gamma receptors and costimulatory molecules on dendritic cells. Immunology. 2009;128(3):334-341.
5. Wijngaarden S, van Roon JA, Bijlsma JW, van de Winkel JG, Lafeber FP. Fcgamma receptor expression levels on monocytes are elevated in rheumatoid arthritis patients with high erythrocyte sedimentation rate who do not use antirheumatic drugs. Rheumatology (Oxford). 2003; 42(5):681-688. (Pubitemid 37220879)
6. Wijngaarden S, van de Winkel JG, Jacobs KM, Bijlsma JW, Lafeber FP, van Roon JA. A shift in the balance of inhibitory and activating Fcγ receptors on monocytes toward the inhibitory FcγRIIb is associated with prevention of monocyte activation in rheumatoid arthritis. Arthritis Rheum. 2004;50(12):3878-3887. (Pubitemid 39643934)
7. Belostocki K, Pricop L, Redecha PB, et al. Infliximab treatment shifts the balance between stimulatory and inhibitory Fc gamma receptor type II isoforms on neutrophils in patients with rheumatoid arthritis. Arthritis Rheum. 2008;58(2):384-388. (Pubitemid 351294873)
8. McGaha TL, Sorrentino B, Ravetch JV. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science. 2005;307(5709): 590-593. (Pubitemid 40165683)
9. Berchtold P, Wenger M. Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: their clinical significance and response to treatment. Blood. 1993;81(5):1246-1250. (Pubitemid 23067361)
10. Kuwana M, Kaburaki J, Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura: role in production of anti-platelet autoantibody. J Clin Invest. 1998;102(7):1393-1402. (Pubitemid 28467568)
11. Clarkson SB, Bussel JB, Kimberly RP, Valinsky JE, Nachman RL, Unkeless JC. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med. 1986;314(19):1236-1239. (Pubitemid 16106411)
12. McKenzie SE, Taylor SM, Malladi P, et al. The role of the human Fc receptor gamma RIIA in the immune clearance of platelets: a transgenic mouse model. J Immunol. 1999;162(7):4311-4318. (Pubitemid 29314823)
13. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory receptor. Science. 2001;291(5503): 445-446.
14. Bruin M, Bierings M, Uiterwaal C, et al. Platelet count, previous infection and FCGR2B genotype predict development of chronic disease in newly diagnosed idiopathic thrombocytopenia in childhood: results of a prospective study. Br J Haematol. 2004;127(5):561-567. (Pubitemid 39627180)
15. Asahi A, Nishimoto T, Okazaki Y, et al. Helicobacter pylori eradication shifts monocyte Fcγ receptor balance toward inhibitory FcgammaRIIB in immune thrombocytopenic purpura patients. J Clin Invest. 2008;118(8):2939-2949.
16. Pels S, Tang C, Ertem M, Beardsley DS. High-dose IgG alters the relative expression of Fc gamma RIIA and Fc gamma RIIb on human macrophages: a mechanism for IVIG therapy in human immune thrombocytopenia [abstract]. Blood. 2009;114:Abstract 683.
17. Crow AR, Song S, Freedman J, et al. IVIG-mediated amelioration of murine ITP via FcγRIIB is independent of SHIP1, SHP-1, and Btk activity. Blood. 2003;102(2):558-560. (Pubitemid 36841975)
18. Mazzucconi MG, Fazi P, Bernasconi S, et al.; Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Thrombocytopenia Working Party. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood. 2007;109(4):1401-1407. (Pubitemid 46239570)
19. Andersen JC. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med. 1994; 330(22):1560-1564. (Pubitemid 24160959)
20. Cheng Y, Wong RS, Soo YO, et al. Initial treatment of immune thrombocytopenic purpura with high dose dexamethasone. N Engl J Med. 2003; 349(9):831-836. (Pubitemid 37025402)
21. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions, and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11): 2386-2393.
22. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002;30(9):1-10.
23. Aslam R, Kim M, Speck ER, et al. Platelet and red blood cell phagocytosis kinetics are differentially controlled by phosphatase activity within mononuclear cells. Transfusion. 2007;47(11): 2161-2168. (Pubitemid 47623986)
24. Semple JW, Aslam R, Kim M, Speck ER, Freedman J. Platelet-bound lipopolysaccharide enhances Fc receptor-mediated phagocytosis of IgG-opsonized platelets. Blood. 2007;109(11): 4803-4805. (Pubitemid 46827774)
25. Olsson M, Bruhns P, Frazier WA, Ravetch JV, Oldenborg PA. Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. Blood. 2005;105(9):3577-3582. (Pubitemid 40628203)
26. Pricop L, Redecha P, Teillaud JL, et al. Differential modulation of stimulatory and inhibitory Fc receptors on human monocytes by Th1 and Th2 cytokine. J Immunol. 2001;166(1):531-537. (Pubitemid 32038473)
27. Semple JW, Milev Y, Cosgrave D, et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood. 1996;87(10):4245-4254. (Pubitemid 26152268)
28. Guo C, Chu X, Shi Y, et al. Correction of Th1-dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura. J Clin Immunol. 2007; 27(6):557-562.
29. Dhodapkar KM, Banerjee D, Connolly J, et al. Selective blockade of the inhibitory Fcgamma receptor (FcgammaRIIB) in human dendritic cells and monocytes induces a type I interferon response program. J Exp Med. 2007;204(6):1359-69. (Pubitemid 46919874)
30. Clatworthy MR, Smith KG. FcgammaRIIb balances efficient pathogen clearance and the cytokine-mediated consequences of sepsis. J Exp Med. 2004;199(5):717-723. (Pubitemid 38316438)
31. Clynes R, Maizes JS, Guinamard R, Ono M, Takai T, Ravetch JV. Modulation of immune complex induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J Exp Med. 1999;189(1):179-185. (Pubitemid 29047037)
32. Tridandapani S, Siefker K, Teillaud JL, Carter JE, Wewers MD, Anderson CL. Regulated expression and inhibitory function of FcgammaRIIb in human monocytic cells. J Biol Chem. 2002;277(7):5082-5089. (Pubitemid 34968549)
33. Comber PG, Rossman MD, Rappaport EF, Chien P, Hogarth PM, Schreiber AD. Modulation of human mononuclear phagocyte FcgammaRII mRNA and protein. Cell Immunol. 1989;124(2): 292-307. (Pubitemid 20012686)
34. Crow AR, Lazarus AH. Role of Fcgamma receptors in the pathogenesis and treatment of idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol. 2003;25(suppl 1):S14-S18. (Pubitemid 37517912)
35. Woods VL Jr., Oh EH, Mason D, McMillan R. Autoantibodies against the platelet glycoprotein IIb/IIIa complex in patients with chronic ITP. Blood. 1984;63(2):368-375. (Pubitemid 14188884)
36. Fujisawa K, Tani P, McMillan R. Platelet-associated antibody to glycoprotein IIb/IIIa from chronic immune thrombocytopenic purpura patients often binds to divalent cation-dependent antigens. Blood. 1993;81(5):1284-1289. (Pubitemid 23067366)
37. Chan H, Moore JC, Finch CN, Warkentin TE, Kelton JG. The IgG subclasses of platelet-associated autoantibodies directed against platelet glycoproteins IIb/IIIa in patients with idiopathic thrombocytopenic purpura. Br J Haematol. 2003; 122(5):818-824. (Pubitemid 37100310)
38. Takai T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol. 2002;2(8):580-592. (Pubitemid 37328733)
39. Kuwana M, Kawakami Y, Ikeda Y. Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with chronic ITP [abstract]. Blood. 2005; 106:Abstract 221.
40. Kuwana M, Okazaki Y, Ikeda Y. Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura. J Thromb Haemost. 2009;7(2):322-329.
41. Ling Y, Cao X, Yu Z, Ruan C. Circulating dendritic cells subsets and CD4+Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome. Eur J Haematol. 2007;79(4):310-316. (Pubitemid 47390130)
42. Shushakova N, Skokowa J, Schulman J, et al. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. J Clin Invest. 2002;110(12):1823-1830. (Pubitemid 36076489)